.Pharmacolibrary.Drugs.ATC.A.A10BX03

Information

Nateglinide is a rapid-acting oral hypoglycemic agent belonging to the meglitinide class used in the treatment of type 2 diabetes mellitus. It stimulates insulin release from pancreatic beta cells and is approved for glycemic control used today.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult subjects after a single oral dose.

References

1. Kirchheiner, J, et al., & Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 44(12) 1209–1225. DOI:10.2165/00003088-200544120-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16372821

2. Kirchheiner, J, et al., & Brockmöller, J (2004). Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clinical pharmacokinetics 43(4) 267–278. DOI:10.2165/00003088-200443040-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15005635

3. Cheng, Y, et al., & Zhou, HH (2013). Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. European journal of clinical pharmacology 69(3) 407–413. DOI:10.1007/s00228-012-1364-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22842957

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)